Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
Arthur KavanaughRene R WesthovensKevin L WinthropSusan J LeeYingMeei TanDi AnLei YeJohn S SundyRobin BesuyenLuc MeulenersMykola StanislavchukAlberto J SpindlerMaria GreenwaldRieke E AltenMark C GenovesePublished in: The Journal of rheumatology (2021)
Filgotinib was well tolerated with a 4-year safety profile comparable to that of the parent trials, both in patients receiving combination therapy with MTX or as monotherapy.